For research use only. Not for therapeutic Use.
Zidebactam（Cat No.:I010149）is a novel beta-lactam enhancer and non-traditional beta-lactamase inhibitor that works synergistically with beta-lactam antibiotics to combat multidrug-resistant Gram-negative bacterial infections. It binds to penicillin-binding protein 2 (PBP2), disrupting bacterial cell wall synthesis, and concurrently inhibits beta-lactamase enzymes, protecting companion antibiotics like cefepime or meropenem from degradation. This dual mechanism is particularly effective against problematic pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa. Zidebactam is a promising solution in antibiotic resistance, enhancing the efficacy of existing antibiotics against resistant bacterial strains.
| Catalog Number | I010149 |
| CAS Number | 1436861-97-0 |
| Synonyms | WCK-5107; WCK 5107; WCK5107; Zidebactam;(1R,2S,5R)-7-oxo-2-(2-((R)-piperidine-3-carbonyl)hydrazine-1-carbonyl)-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate |
| Molecular Formula | C13H21N5O7S |
| Purity | ≥95% |
| Target | Penicillin-binding protein (PBP) |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | [(2S,5R)-7-oxo-2-[[[(3R)-piperidine-3-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate |
| InChI | InChI=1S/C13H21N5O7S/c19-11(8-2-1-5-14-6-8)15-16-12(20)10-4-3-9-7-17(10)13(21)18(9)25-26(22,23)24/h8-10,14H,1-7H2,(H,15,19)(H,16,20)(H,22,23,24)/t8-,9-,10+/m1/s1 |
| InChIKey | YCZPXRQPDCXTIO-BBBLOLIVSA-N |
| SMILES | C1C[C@H](CNC1)C(=O)NNC(=O)[C@@H]2CC[C@@H]3CN2C(=O)N3OS(=O)(=O)O |
| Reference | </br>1:WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M.J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050. PMID: 28333332 </br>2:WCK 5107 (Zidebactam) & WCK 5153: Novel inhibitors of PBP2 showing potent /β-lactam enhancer/ activity against <i>Pseudomonas aeruginosa</i>, including multidrug-resistant metallo-β-lactamase-producing high-risk clones. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A.Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02529-16. doi: 10.1128/AAC.02529-16. [Epub ahead of print] PMID: 28289035 </br>3:WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK.Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00072-17. doi: 10.1128/AAC.00072-17. Print 2017 May. PMID: 28242660 </br>4:In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N.J Antimicrob Chemother. 2017 Feb 3. doi: 10.1093/jac/dkw593. [Epub ahead of print] No abstract available. PMID: 28158732 |
